

U.S.S.N. 09/727,873
Filed: December 1, 2000
AMENDMENT

APPENDIX: Clean Copy of Claims as Amended

a, 1. (amended) A method to decrease fibrous tissue size comprising administering to an individual in need of treatment thereof an effective amount of a dermatan sulfate or chondroitin sulfate degrading enzyme to decrease fibrous cell proliferative response to growth factors, reduce secretion of collagen by fibroblasts, and thereby decrease the size of fibrous tissue.

2. The method of claim 1 wherein the enzyme is selected from the group consisting of bacterial dermatan or chondroitin sulfate degrading enzyme and is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aureescens*, arylsulfatase B, N-acetylgalactosamine-6-sulfatase and iduronate sulfatase from mammalian cells, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.

3. The method of claim 1 wherein the enzyme is a mammalian enzyme.
4. The method of claim 1 wherein the enzyme is a bacterial enzyme.
5. The method of claim 4 wherein the chondroitinase is chondroitinase B.
6. The method of claim 1 wherein the individual has a skin disorder.

U.S.S.N. 09/727,873
Filed: December 1, 2000
AMENDMENT

7. The method of claim 6 wherein the skin disorder is scleroderma or psoriasis.

8. The method of claim 1 wherein the individual has keloid scarring or is at risk of keloid scarring, or has pulmonary fibrosis.

9. The method of claim 1 wherein the enzyme is administered systemically.

10. The method of claim 1 wherein the enzyme is administered topically or locally at or adjacent to a site in need of treatment.

11. The method of claim 1 wherein the enzyme is administered in a controlled and/or sustained release formulation.

ATL1 #493565 v1